• SINOPEG Gained Substantial Achievement in CPhI Worldwide 2019
    SINOPEG Gained Substantial Achievement in CPhI Worldwide 2019 2019-11-20
    CPhI Worldwide 2019 was held successfully in Frankfurt, Germany from Nov. 5th-7th. SINOPEG's CEO Dr. Wengui Weng and sales manager Mr. Lingnan Chen attended this exhibition. Our booth Number is 41K60. We SINOPEG was established in 2011, and specilized in PEG derivatives, PEG block-copolymer, side chain of diabetes medications etc.. We are not only maintain the advantage of old products, but also continue to work on the development of new products.   During the exhibition, many customers visited our booth. We had very deep discusstion with our old customers and partners regarding some issues and problems of ongoing projects, and reached agreements for the further programs. Besides, we also received many new potential customers from all over the world. They showed great interest in our products, and made preliminary cooperation intention with us. Thanks very much for the support and trust from all friends, customers and partners! We hope we can have close cooperation together, and reach win-win achievement in the future.
    View More
  • Tetra-PEG Based Hydrogel Sealants for In Vivo Visceral  Hemostasis
    Tetra-PEG Based Hydrogel Sealants for In Vivo Visceral Hemostasis 2019-11-08
           Tetra-PEG hydrogels based on the ammonolysis reaction between tetra-armed poly(ethylene glycol) amine (Tetra-PEG-NH2) and Tetra-PEG-SAE offer massive advantages as sealants. They are entirely synthetic without the misgivings of being inhibited by anticoagulation agents and transferring disease. Their cost is low due to their easily preservable components with high accessibility. Because of the intrinsic properties of this ammonolysis reaction, the resulting hydrogels can gel  fast just by injection and adhere to the tissues tightly throughchemical bonds. Another remarkable advantage for Tetra-PEG hydrogels is that they are mechanically tough, and the sealants are favored to be mechanically tough to keep stable in case of dynamic movement of the tissues and the use of assistant pressure which is a key adjunctive step in achieving hemostasis.        However, two hurdles are preventing extending their applications in vivo. The first one is that just as commercialized sealants, none of the reported Tetra-PEG hydrogels could be controllably removed without mechanical debridement, which is extremely dangerous because of their high mechanical strength. Besides, they possess long degradation time, which will lead to severe foreign body reactions, tissue adhesion, disturbed tissue healing, and obstruction of the circulatory system, when used in vivo. Here, to overcome the limitations of the existing ammonolysis based Tetra-PEG hydrogels, we construct an optimized one (SS) with fast degradable and controllably dissolvable properties via Tetra-PEG-NH2 and tetra-armed poly(ethylene glycol) succinimidyl succinate (Tetra-PEG-SS) (Figure 1a and Figures S1 and S2, Supporting Information). The resulting SS exhibits biocompatibility superior to the reported degradable Tetra-PEG hydrogel (SG) based on Tetra-PEG-NH2 and tetra-armed poly(ethylene glycol) succinimidyl glutarate (Tetra-PEG-SG) (Figure 1b and Figures S3 and S4, Supporting Information). More importantly, in contrast to the disappointing results of SG that leads to serious adverse effects in in vivo hemostasis due to the long retention, SS causes almost no noticeable side effects with outstanding hemostasis efficacy even under the anticoagulated situations. This hydrogel is a promising candidate for the next-generation in vivo sealants in the aged society.
    View More
  • Visit SINOPEG at 2019 CPhI Worldwide, Germany
first page 1 2 3 last page

A total of 3 pages

Copyright © XIAMEN SINOPEG BIOTECH CO., LTD. All Rights Reserved.